DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for morbid obesity — screening already-approved drugs against its 38-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMorbid obesity maps to a 38-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for morbid obesity is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
neuronal pentraxin 1 (NPTX1) — NPTX1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cacdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6YPE · 1.45 Å · ligand CACODYLATE ION (CAC). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Southern Medical Journal · 1998 · 42 citations
Disorders Associated With Clinically Severe Obesity: Significant Improvement After Surgical Weight Reduction
AbstractBACKGROUND: Surgical treatment for patients with clinically severe obesity mainly aims to reduce morbidity. METHODS: Sixty-two patients were examined for disorders associated with morbid obesity before and after surgical weight reduction by vertical banded gastroplasty. All patients were followed-up for 12 to 48 months. RESULTS: At the end of the first postoperative year, 84% of the patients had lost at least 50% of their excess weight. Of the 218 weight-related pathologic conditions existing before the operation, 131 (60%) were completely cured, 50 (23%) showed significant improvement, and only 37 (17%) remained unchanged. The same percentages were obtained for patients followed tip for 24, 36, and 48 postoperative months. CONCLUSIONS: Surgical treatment of clinically severe obesity has a significant effect on the health of the patients by eliminating the associated disorders.
Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · 2023 · 0 citations · open access
Mini gastric bypass for weight gain after sleeve gastrectomy
AbstractBackground: Surgery for morbid obesity causes a significant, sustained weight loss that lowers obesity-related morbidity and improves survival as compared to those getting optimal medical treatment. Long-term SG outcomes with over 10 years of follow-up have recently become available, and they show that those who come with weight loss failure (WLF) due to insufficient weight loss (IWL) or weight regain (WR) and/or complications like gastroesophageal reflux disease (GERD). So, revisional surgery following SG is becoming more prevalent for bariatric surgeons. Following a failed sleeve gastrectomy, LMGB was recently used as a complementary procedure; this study aimed to examine the viability, mortality, morbidity, and short-term weight loss outcomes of laparoscopic mini gastric bypass when used as an additional malabsorptive procedure for those who underwent SG but experienced insufficient weight loss or weight regain. Patients and method: A prospective observational study comprised of 20 patients with weight loss failure either due to insufficient weight loss or weight regain following LSG. Between December 2021 and December 2022, laparoscopic mini-gastric bypass procedures were conducted at Al-Azhar University Hospitals' surgical department in Cairo, Egypt, along with 1 year of postsurgical patient follow-up. Results and conclusion: The mini-gastric bypass operation contributed to significant weight loss, with a mean BMI of 53.66 kg/m2 before the revision and 33.86 kg/m2 one year following the revision, and it also contributed to a clear improvement in some diseases related to patients with obesity, like type 2 diabetes by 75% and hypertension by 50%.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
